CNS Pharmaceuticals, Inc. (CNSP) Cash Flow Statement
Where CNSP’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$13.8M
- Capital expenditures
- $18,175
- Free cash flow
- −$13.8M
- Returned to shareholders
- $2,043
- Change in cash
- $739,636 cash at year-end $7.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
CNSP operating cash flow, capex and free cash flow
CNSP cash flow trends, 2017–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$112,1972017 | −$13.8M2025 | — | |
| Capital expenditures | $32017 | $18,1752025 | +197.0%/yr | |
| Free cash flow | −$112,1972017 | −$13.8M2025 | — | |
| Stock-based compensation | $119,8542017 | $187,7282025 | +5.8%/yr | |
| Share buybacks (net) | $02017 | $2,0432025 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CNSP cash flow by activity
CNSP net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CNSP cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||
| Net income | −$15.9M | −$14.9M | −$18.9M | −$15.3M | −$14.5M | −$9.5M | −$3.9M | −$7.4M | −$219,362 |
| Depreciation & amortization | $3,918 | $3,306 | $4,134 | $11,756 | $13,070 | $11,096 | $1,955 | $881,787 | $2,342 |
| Stock-based compensation | $187,728 | $838,957 | $1.0M | $1.2M | $1.7M | $1.3M | $477,096 | $110,240 | $119,854 |
| Change in working capital | $1.8M | −$3.7M | $3.7M | $3.2M | −$780,021 | $833,782 | −$425,619 | $83,777 | $47,250 |
| Other non-cash items | $2,559 | $596,113 | $498 | $337,249 | $0 | $1,583 | $270,307 | $5.6M | −$62,281 |
| Cash from operating activities | −$13.8M | −$17.1M | −$14.1M | −$10.6M | −$13.5M | −$7.3M | −$3.6M | −$716,385 | −$112,197 |
| Investing activities | |||||||||
| Capital expenditures | −$18,175 | −$4,188 | −$3,901 | −$4,422 | −$5,748 | −$17,945 | −$20,120 | −$5 | −$3 |
| Investments (net) | — | −$4,188 | −$1,743 | −$4,422 | −$5,748 | −$17,945 | −$20,120 | — | — |
| Acquisitions & other investing | $0 | $4,188 | $1,743 | $4,422 | $5,748 | $17,945 | $20,120 | −$20,115 | −$20,117 |
| Cash from investing activities | −$18,175 | −$4,188 | −$3,901 | −$4,422 | −$5,748 | −$17,945 | −$20,120 | −$20,120 | −$20,120 |
| Financing activities | |||||||||
| Share repurchases & issuance (net) | −$2,043 | $0 | — | — | — | $14.2M | $10.3M | $390,500 | $100,920 |
| Net borrowing (repayment) | −$297,553 | −$300,806 | −$438,733 | −$427,700 | −$477,490 | −$88,081 | −$35,000 | $886,675 | $292,380 |
| Shares issued | $14.0M | $23.4M | $7.5M | $16.0M | $4.7M | $14.2M | $10.3M | $390,500 | $0 |
| Other financing | $822,084 | −$45,425 | −$2.4M | $2,734 | $332,750 | −$14.2M | −$10.3M | −$506,700 | −$170,560 |
| Cash from financing activities | $14.6M | $23.0M | $4.6M | $15.6M | $4.5M | $14.1M | $10.3M | $1.2M | $222,740 |
| Summary | |||||||||
| Net change in cash | $739,636 | $5.9M | −$9.5M | $5.1M | −$9.0M | $6.8M | $6.7M | $444,590 | $110,543 |
| Cash at end of period | $7.2M | $6.5M | $548,721 | $10.1M | $5.0M | $14.0M | $7.2M | $555,133 | $110,543 |
| Free cash flow | −$13.8M | −$17.1M | −$14.1M | −$10.6M | −$13.5M | −$7.3M | −$3.6M | −$716,385 | −$112,197 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$2.6M | −$4.9M | −$6.0M | −$3.2M | −$2.4M | −$4.3M | −$3.2M | −$5.6M | −$2.5M | −$3.5M | −$5.4M | −$4.5M |
| Depreciation & amortization | $11,132 | $1,868 | $1,020 | $697 | $1,101 | $1,100 | $985 | $751 | $752 | $818 | $953 | $899 |
| Stock-based compensation | $2,445 | $2,555 | $85,068 | $18,452 | $21,841 | $62,367 | $129,900 | $271,779 | $234,345 | $202,933 | $232,675 | $194,759 |
| Change in working capital | −$965,005 | $284,005 | −$999,349 | $1.0M | −$3.0M | $995,946 | −$2.4M | −$794,393 | $645,263 | $149,130 | $2.6M | $950,061 |
| Other non-cash items | $0 | $0 | $3.8M | $1 | $0 | $0 | $1 | −$672,193 | $0 | −$190 | −$259 | $757 |
| Cash from operating activities | −$3.5M | −$4.6M | −$3.1M | −$2.2M | −$5.3M | −$3.2M | −$5.5M | −$6.8M | −$1.7M | −$3.2M | −$2.5M | −$3.4M |
| Investing activities | ||||||||||||
| Capital expenditures | −$3,821 | −$6,179 | −$18,175 | $0 | $0 | −$4,188 | −$4,188 | −$3 | −$3 | −$3 | −$2,157 | −$1,744 |
| Investments (net) | — | — | — | — | — | — | −$4,188 | — | — | — | −$2,157 | −$1,744 |
| Acquisitions & other investing | $0 | $0 | $0 | — | — | $0 | $4,188 | — | — | −$2,154 | — | $1,744 |
| Cash from investing activities | −$3,821 | −$6,179 | −$18,175 | — | — | −$4,188 | −$4,188 | — | — | −$2,157 | — | −$1,744 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | $0 | $0 | −$1,114 | $557 | −$443 | −$557 | — | $0 | $0 | $0 | — | — |
| Net borrowing (repayment) | −$90,782 | −$96,218 | −$30,791 | −$90,974 | −$88,906 | −$86,882 | −$31,187 | −$92,061 | — | — | — | — |
| Shares issued | $20.7M | $500,878 | $501,745 | $0 | $4.5M | $9.0M | $5.0M | $12.4M | $2.4M | $3.5M | $215,641 | $132,851 |
| Other financing | −$39,000 | $0 | −$62,968 | −$1,199 | $3,226 | $882,539 | −$10,001 | −$40,000 | −$97,685 | −$75,297 | $2.0M | −$124,492 |
| Cash from financing activities | $20.6M | $404,660 | $406,872 | −$91,616 | $4.4M | $9.8M | $5.0M | $12.3M | $2.3M | $3.5M | $2.2M | $8,359 |
| Summary | ||||||||||||
| Net change in cash | $17.0M | −$4.3M | −$2.7M | −$2.3M | −$917,719 | $6.6M | −$511,746 | $5.5M | $676,333 | $266,505 | −$360,826 | −$3.4M |
| Cash at end of period | $20.0M | $3.0M | $7.2M | $9.9M | $12.1M | $13.0M | $6.5M | $7.0M | $1.5M | $815,226 | $548,721 | $909,547 |
| Free cash flow | −$3.5M | −$4.7M | −$3.1M | −$2.2M | −$5.3M | −$3.2M | −$5.5M | −$6.8M | −$1.7M | −$3.2M | −$2.5M | −$3.4M |
| Free cash flow margin | — | — | — | — | — | −103,245.4% | −174,364.6% | — | — | −50,173.8% | — | — |
| Capex / revenue | — | — | — | — | — | 133.4% | 133.4% | — | — | 0.0% | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CNSP cash generation
In fiscal 2025 (ended December 31, 2025), CNS Pharmaceuticals generated -$13.8 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$13.8 million. It returned $0.0 million to shareholders through dividends ($0) and net share buybacks ($0.0 million). Cash and equivalents rose by $0.7 million over the year.
Related: CNSP income statement, CNSP balance sheet. See the CNSP stock overview for the latest quote and news.
CNSP cash flow FAQ
What is CNS Pharmaceuticals's free cash flow?
CNS Pharmaceuticals's free cash flow was -$13.8 million in fiscal 2025: -$13.8 million of operating cash flow minus $0.0 million of capital expenditures It was -$17.1 million a year earlier..
How much cash does CNS Pharmaceuticals generate from operations?
CNS Pharmaceuticals generated -$13.8 million of cash from operating activities in fiscal 2025.
How much does CNS Pharmaceuticals spend on capital expenditures?
CNS Pharmaceuticals spent $0.0 million on capital expenditures in fiscal 2025, compared with $0.0 million the year before.
How much stock does CNS Pharmaceuticals buy back?
CNS Pharmaceuticals spent $0.0 million on net share repurchases in fiscal 2025.